<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37711069</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-3004</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Molecular medicine reports</Title><ISOAbbreviation>Mol Med Rep</ISOAbbreviation></Journal><ArticleTitle>Immune podocytes in the immune microenvironment of lupus nephritis (Review).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">204</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3892/mmr.2023.13091</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder caused by the loss of tolerance to endogenous nuclear antigens such as double&#x2011;stranded DNA, leading to the proliferation of T cells and subsequent activation of B cells, which results in serious organ damage and life&#x2011;threatening complications such as lupus nephritis. Lupus nephritis (LN) develops as a frequent complication of SLE, accounting for &gt;60% of SLE cases, and is characterized by proteinuria and heterogeneous histopathological findings. Glomerular injury serves a role in proteinuria as podocyte damage is the leading contributor. Numerous studies have reported that podocytes are involved in the immune response that promotes LN progression. In LN, immune complex deposition stimulates dendritic cells to secrete inflammatory cytokines that activate T cells and B cells. B cells secrete autoantibodies that attack and damage the renal podocytes, leading to renal podocyte injury. The injured podocytes trigger inflammatory cells through the expression of toll&#x2011;like receptors and trigger T cells through major histocompatibility complexes and CD86, thereby participating in the local immune response and the exacerbation of podocyte injury. Based on the existing literature, the present review summarizes the research progress of podocytes in LN under the local immune microenvironment of the kidney, explores the mechanism of podocyte injury under the immune microenvironment, and evaluates podocytes as a potential therapeutic target for LN.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Ruiling</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Basic Medical College, Shanxi Medical University, Jinzhong, Shanxi 030619, P.R.&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wen</LastName><ForeName>Xiaoting</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R.&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Peng</LastName><ForeName>Xinyue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi 030032, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Miaomiao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi 030032, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mi</LastName><ForeName>Liangyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi 030032, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Jiamin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R.&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Mol Med Rep</MedlineTA><NlmUniqueID>101475259</NlmUniqueID><ISSNLinking>1791-2997</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050199" MajorTopicYN="Y">Podocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">immune microenvironment</Keyword><Keyword MajorTopicYN="N">immune podocyte</Keyword><Keyword MajorTopicYN="N">immunosuppressants</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">treatment strategy</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>15</Day><Hour>3</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37711069</ArticleId><ArticleId IdType="pmc">PMC10540031</ArticleId><ArticleId IdType="doi">10.3892/mmr.2023.13091</ArticleId><ArticleId IdType="pii">204</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82:351&#x2013;356. doi: 10.1136/ard-2022-223035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223035</ArticleId><ArticleId IdType="pmc">PMC9933169</ArticleId><ArticleId IdType="pubmed">36241363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971&#x2013;2015: A systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68:1432&#x2013;1441. doi: 10.1002/art.39594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39594</ArticleId><ArticleId IdType="pmc">PMC5071782</ArticleId><ArticleId IdType="pubmed">26815601</ArticleId></ArticleIdList></Reference><Reference><Citation>Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the development of lupus nephritis: A retrospective analysis. Am J Med. 2002;112:726&#x2013;729. doi: 10.1016/S0002-9343(02)01118-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(02)01118-X</ArticleId><ArticleId IdType="pubmed">12079714</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre A, Izadi Z, Trupin L, Barbour KE, Greenlund KJ, Katz P, Lanata C, Criswell L, Dall'Era M, Yazdany J. Race, ethnicity, and disparities in the risk of end-organ lupus manifestations following a systemic lupus erythematosus diagnosis in a multiethnic cohort. Arthritis Care Res (Hoboken) 2023;75:34&#x2013;43. doi: 10.1002/acr.24892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24892</ArticleId><ArticleId IdType="pmc">PMC9587136</ArticleId><ArticleId IdType="pubmed">35452566</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Costa RP, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716&#x2013;730. doi: 10.1038/nrrheum.2016.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015;11:329&#x2013;341. doi: 10.1038/nrneph.2015.33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2015.33</ArticleId><ArticleId IdType="pubmed">25825084</ArticleId></ArticleIdList></Reference><Reference><Citation>Costenbader KH, Desai A, Alarc&#xf3;n GS, Hiraki LT, Shaykevich T, Brookhart MA, Massarotti E, Lu B, Solomon DH, Winkelmayer WC. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63:1681&#x2013;1688. doi: 10.1002/art.30293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30293</ArticleId><ArticleId IdType="pmc">PMC3106117</ArticleId><ArticleId IdType="pubmed">21445962</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016;27:2929&#x2013;2939. doi: 10.1681/ASN.2016040415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016040415</ArticleId><ArticleId IdType="pmc">PMC5042683</ArticleId><ArticleId IdType="pubmed">27283496</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A. What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol. 2016;12:143&#x2013;153. doi: 10.1038/nrrheum.2015.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.159</ArticleId><ArticleId IdType="pmc">PMC4820834</ArticleId><ArticleId IdType="pubmed">26581344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16:175&#x2013;179. doi: 10.1681/ASN.2004050350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2004050350</ArticleId><ArticleId IdType="pubmed">15548564</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomback AS, Markowitz GS. Lupus podocytopathy: A distinct entity. Clin J Am Soc Nephrol. 2016;11:547&#x2013;548. doi: 10.2215/CJN.01880216.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01880216</ArticleId><ArticleId IdType="pmc">PMC4822655</ArticleId><ArticleId IdType="pubmed">26983708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright RD, Beresford MW. Podocytes contribute, and respond, to the inflammatory environment in lupus nephritis. Am J Physiol Renal Physiol. 2018;315:F1683&#x2013;F1694. doi: 10.1152/ajprenal.00512.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00512.2017</ArticleId><ArticleId IdType="pmc">PMC6336988</ArticleId><ArticleId IdType="pubmed">30207171</ArticleId></ArticleIdList></Reference><Reference><Citation>Moustafa FE, Soliman NA, Bakr AM, El Shwaf IM. Assessment of detached podocytes in the Bowman's space as a marker of disease activity in lupus nephritis. Lupus. 2014;23:146&#x2013;150. doi: 10.1177/0961203313514125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313514125</ArticleId><ArticleId IdType="pubmed">24306541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Chen Y, Wang S, Chen H, Liu Z, Zeng C, Zhang H, Liu Z. Clinical-Morphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol. 2016;11:585&#x2013;592. doi: 10.2215/CJN.06720615.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.06720615</ArticleId><ArticleId IdType="pmc">PMC4822663</ArticleId><ArticleId IdType="pubmed">26983707</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaly S, Rakaee M, Abdi R, Tsokos GC, Fenton KA. Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis. Autoimmun Rev. 2021;20:102980. doi: 10.1016/j.autrev.2021.102980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102980</ArticleId><ArticleId IdType="pubmed">34718163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S, Fedoriw Y, Brenneman EK, Truong YK, Kikly K, Vilen BJ. BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J Immunol. 2017;198:2602&#x2013;2611. doi: 10.4049/jimmunol.1600281.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600281</ArticleId><ArticleId IdType="pmc">PMC5360485</ArticleId><ArticleId IdType="pubmed">28235864</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol. 2014;26:502&#x2013;509. doi: 10.1097/BOR.0000000000000089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000089</ArticleId><ArticleId IdType="pmc">PMC4221732</ArticleId><ArticleId IdType="pubmed">25014039</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieker J, Tel J, Pieterse E, Thielen A, Rother N, Bakker M, Fransen J, Dijkman HB, Berden JH, de Vries JM, et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol. 2016;68:462&#x2013;472. doi: 10.1002/art.39417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39417</ArticleId><ArticleId IdType="pubmed">26360137</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon KB. Review: Cell death, nucleic acids, and immunity: Inflammation beyond the grave. Arthritis Rheumatol. 2018;70:805&#x2013;816. doi: 10.1002/art.40452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40452</ArticleId><ArticleId IdType="pmc">PMC5984680</ArticleId><ArticleId IdType="pubmed">29439290</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvi V, Gianello V, Busatto S, Bergese P, Andreoli L, D'Oro U, Zingoni A, Tincani A, Sozzani S, Bosisio D. Exosome-delivered microRNAs promote IFN-&#x3b1; secretion by human plasmacytoid DCs via TLR7. JCI Insight. 2018;3:e98204. doi: 10.1172/jci.insight.98204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.98204</ArticleId><ArticleId IdType="pmc">PMC6012509</ArticleId><ArticleId IdType="pubmed">29769437</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard D, Eloranta ML, Hagberg N, Berggren O, Tandre K, Alm G, R&#xf6;nnblom L. Activated T cells enhance interferon-&#x3b1; production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Ann Rheum Dis. 2016;75:1728&#x2013;1734. doi: 10.1136/annrheumdis-2015-208055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208055</ArticleId><ArticleId IdType="pubmed">26493814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L, Zhang B, Wu X, Liu R, Fan H, Han L, Zhang Z, Ma X, Chu CQ, Shi X. Toll-like receptors 7 and 9 regulate the proliferation and differentiation of B cells in systemic lupus erythematosus. Front Immunol. 2023;14:1093208. doi: 10.3389/fimmu.2023.1093208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1093208</ArticleId><ArticleId IdType="pmc">PMC9975558</ArticleId><ArticleId IdType="pubmed">36875095</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrezenmeier E, Jayne D, D&#xf6;rner T. Targeting B cells and plasma cells in glomerular diseases: Translational perspectives. J Am Soc Nephrol. 2018;29:741&#x2013;758. doi: 10.1681/ASN.2017040367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2017040367</ArticleId><ArticleId IdType="pmc">PMC5827591</ArticleId><ArticleId IdType="pubmed">29326157</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Mendoza G, Sans&#xf3;n SP, Rodr&#xed;guez-Castro S, Crisp&#xed;n JC, Rosetti F. Mechanisms of tissue injury in lupus nephritis. Trends Mol Med. 2018;24:364&#x2013;378. doi: 10.1016/j.molmed.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2018.02.003</ArticleId><ArticleId IdType="pubmed">29526595</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: Core curriculum 2020. Am J Kidney Dis. 2020;76:265&#x2013;281. doi: 10.1053/j.ajkd.2019.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M, Vignesh P, Tiewsoh K, Rawat A. Revisiting the complement system in systemic lupus erythematosus. Expert Rev Clin Immunol. 2020;16:397&#x2013;408. doi: 10.1080/1744666X.2020.1745063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2020.1745063</ArticleId><ArticleId IdType="pubmed">32228236</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavenst&#xe4;dt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83:253&#x2013;307. doi: 10.1152/physrev.00020.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00020.2002</ArticleId><ArticleId IdType="pubmed">12506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P. A review of podocyte biology. Am J Nephrol. 2018;47((Suppl 1)):S3&#x2013;S13. doi: 10.1159/000481633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000481633</ArticleId><ArticleId IdType="pubmed">29852492</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries JD, Wang P, Streuli C, Geiger B, Humphries MJ, Ballestrem C. Vinculin controls focal adhesion formation by direct interactions with talin and actin. J Cell Biol. 2007;179:1043&#x2013;1057. doi: 10.1083/jcb.200703036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200703036</ArticleId><ArticleId IdType="pmc">PMC2099183</ArticleId><ArticleId IdType="pubmed">18056416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellin L, Huber TB, Gerke P, Quack I, Pavenst&#xe4;dt H, Walz G. NEPH1 defines a novel family of podocin interacting proteins. FASEB J. 2003;17:115&#x2013;117. doi: 10.1096/fj.02-0242fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-0242fje</ArticleId><ArticleId IdType="pubmed">12424224</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P, Verma R, Nihalani D, Johnstone DB, Holzman LB. Neph1 cooperates with nephrin to transduce a signal that induces actin polymerization. Mol Cell Biol. 2007;27:8698&#x2013;8712. doi: 10.1128/MCB.00948-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00948-07</ArticleId><ArticleId IdType="pmc">PMC2169393</ArticleId><ArticleId IdType="pubmed">17923684</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber TB, Simons M, Hartleben B, Sernetz L, Schmidts M, Gundlach E, Saleem MA, Walz G, Benzing T. Molecular basis of the functional podocin-nephrin complex: Mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum Mol Genet. 2003;12:3397&#x2013;3405. doi: 10.1093/hmg/ddg360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg360</ArticleId><ArticleId IdType="pubmed">14570703</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryer SE, Reiser J. TRPC6 channels and their binding partners in podocytes: Role in glomerular filtration and pathophysiology. Am J Physiol Renal Physiol. 2010;299:F689&#x2013;F701. doi: 10.1152/ajprenal.00298.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00298.2010</ArticleId><ArticleId IdType="pmc">PMC2957253</ArticleId><ArticleId IdType="pubmed">20685822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha TS. Roles of adaptor proteins in podocyte biology. World J Nephrol. 2013;2:1&#x2013;10. doi: 10.5527/wjn.v2.i1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.5527/wjn.v2.i1.1</ArticleId><ArticleId IdType="pmc">PMC3782205</ArticleId><ArticleId IdType="pubmed">24175259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Yu F, Song D, Wang SX, Zhao MH. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: A large cohort study from a single centre. Rheumatology (Oxford) 2014;53:1235&#x2013;1244. doi: 10.1093/rheumatology/ket491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket491</ArticleId><ArticleId IdType="pubmed">24599917</ArticleId></ArticleIdList></Reference><Reference><Citation>Banas MC, Banas B, Hudkins KL, Wietecha TA, Iyoda M, Bock E, Hauser P, Pippin JW, Shankland SJ, Smith KD, et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol. 2008;19:704&#x2013;713. doi: 10.1681/ASN.2007040395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2007040395</ArticleId><ArticleId IdType="pmc">PMC2390962</ArticleId><ArticleId IdType="pubmed">18256364</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ding F, Zhang X, Li B, Ding J. The expression profile of complement components in podocytes. Int J Mol Sci. 2016;17:471. doi: 10.3390/ijms17040471.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17040471</ArticleId><ArticleId IdType="pmc">PMC4848927</ArticleId><ArticleId IdType="pubmed">27043537</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Cui Z, Zhao MH. Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy. J Am Soc Nephrol. 2022;33:1742&#x2013;1756. doi: 10.1681/ASN.2021101384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021101384</ArticleId><ArticleId IdType="pmc">PMC9529185</ArticleId><ArticleId IdType="pubmed">35777783</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Lv D, Jiang S, Hou Q, Zhang L, Li S, Zhu X, Xu X, Wen J, Zeng C, et al. Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction. Cell Death Dis. 2022;13:281. doi: 10.1038/s41419-022-04737-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04737-5</ArticleId><ArticleId IdType="pmc">PMC8964685</ArticleId><ArticleId IdType="pubmed">35351877</ArticleId></ArticleIdList></Reference><Reference><Citation>Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ. DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest. 2003;111:877&#x2013;885. doi: 10.1172/JCI200315645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200315645</ArticleId><ArticleId IdType="pmc">PMC153762</ArticleId><ArticleId IdType="pubmed">12639994</ArticleId></ArticleIdList></Reference><Reference><Citation>Appay MD, Kazatchkine MD, Levi-Strauss M, Hinglais N, Bariety J. Expression of CR1 (CD35) mRNA in podocytes from adult and fetal human kidneys. Kidney Int. 1990;38:289&#x2013;293. doi: 10.1038/ki.1990.198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1990.198</ArticleId><ArticleId IdType="pubmed">2402120</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira JE, Costa RS, Lachmann PJ, W&#xfc;rzner R, Barbosa JE. CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients. Clin Exp Immunol. 1996;105:497&#x2013;503. doi: 10.1046/j.1365-2249.1996.d01-776.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1996.d01-776.x</ArticleId><ArticleId IdType="pmc">PMC2200531</ArticleId><ArticleId IdType="pubmed">8809140</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll S, Miot S, Sadallah S, Gudat F, Mihatsch MJ, Schifferli JA. No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int. 2001;59:160&#x2013;168. doi: 10.1046/j.1523-1755.2001.00476.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2001.00476.x</ArticleId><ArticleId IdType="pubmed">11135068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Haas M, Quigg RJ. Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2011;22:285&#x2013;295. doi: 10.1681/ASN.2010060647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2010060647</ArticleId><ArticleId IdType="pmc">PMC3029901</ArticleId><ArticleId IdType="pubmed">21148254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, Terence Cook H, Cairns TD. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 2015;54:2286&#x2013;2288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643725</ArticleId><ArticleId IdType="pubmed">26316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I, Schieppati A, Noris M, Tovo PA, Remuzzi G. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol. 2015;30:167&#x2013;172. doi: 10.1007/s00467-014-2944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-014-2944-y</ArticleId><ArticleId IdType="pubmed">25173358</ArticleId></ArticleIdList></Reference><Reference><Citation>Patole PS, Pawar RD, Lech M, Zecher D, Schmidt H, Segerer S, Ellwart A, Henger A, Kretzler M, Anders HJ. Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice. Nephrol Dial Transplant. 2006;21:3062&#x2013;3073. doi: 10.1093/ndt/gfl336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfl336</ArticleId><ArticleId IdType="pubmed">16954173</ArticleId></ArticleIdList></Reference><Reference><Citation>Devarapu SK, Anders HJ. Toll-like receptors in lupus nephritis. J Biomed Sci. 2018;25:35. doi: 10.1186/s12929-018-0436-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-018-0436-2</ArticleId><ArticleId IdType="pmc">PMC5898010</ArticleId><ArticleId IdType="pubmed">29650017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura J, Ichii O, Miyazono K, Nakamura T, Horino T, Otsuka-Kanazawa S, Kon Y. Overexpression of Toll-like receptor 8 correlates with the progression of podocyte injury in murine autoimmune glomerulonephritis. Sci Rep. 2014;4:7290. doi: 10.1038/srep07290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07290</ArticleId><ArticleId IdType="pmc">PMC4252901</ArticleId><ArticleId IdType="pubmed">25468389</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: The role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol. 2007;25:419&#x2013;441. doi: 10.1146/annurev.immunol.22.012703.104514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.22.012703.104514</ArticleId><ArticleId IdType="pubmed">17378763</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Lichtnekert J, Allam R. Interferon-alpha and -beta in kidney inflammation. Kidney Int. 2010;77:848&#x2013;854. doi: 10.1038/ki.2010.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2010.71</ArticleId><ArticleId IdType="pubmed">20237459</ArticleId></ArticleIdList></Reference><Reference><Citation>Machida H, Ito S, Hirose T, Takeshita F, Oshiro H, Nakamura T, Mori M, Inayama Y, Yan K, Kobayashi N, Yokota S. Expression of Toll-like receptor 9 in renal podocytes in childhood-onset active and inactive lupus nephritis. Nephrol Dial Transplant. 2010;25:2530&#x2013;2537. doi: 10.1093/ndt/gfq058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfq058</ArticleId><ArticleId IdType="pubmed">20181802</ArticleId></ArticleIdList></Reference><Reference><Citation>Masum MA, Ichii O, Hosny Ali Elewa Y, Nakamura T, Otani Y, Hosotani M, Kon Y. Overexpression of toll-like receptor 9 correlates with podocyte injury in a murine model of autoimmune membranoproliferative glomerulonephritis. Autoimmunity. 2018;51:386&#x2013;398. doi: 10.1080/08916934.2018.1549234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2018.1549234</ArticleId><ArticleId IdType="pubmed">30592438</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano Y, Yamauchi K, Hayakawa K, Hiramatsu N, Kasai A, Okamura M, Yokouchi M, Shitamura A, Yao J, Kitamura M. Transcriptional suppression of nephrin in podocytes by macrophages: Roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett. 2007;581:421&#x2013;426. doi: 10.1016/j.febslet.2006.12.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2006.12.051</ArticleId><ArticleId IdType="pubmed">17239861</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Niu L, Tang X, Feng R, Yao G, Chen W, Li W, Feng X, Chen H, Sun L. Mesenchymal stem cells prevent podocyte injury in lupus-prone B6.MRL-Faslpr mice via polarizing macrophage into an anti-inflammatory phenotype. Nephrol Dial Transplant. 2019;34:597&#x2013;605. doi: 10.1093/ndt/gfy195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfy195</ArticleId><ArticleId IdType="pubmed">29982691</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung SJ, Fu SM. Interactions among glomerulus infiltrating macrophages and intrinsic cells via cytokines in chronic lupus glomerulonephritis. J Autoimmun. 2020;106:102331. doi: 10.1016/j.jaut.2019.102331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102331</ArticleId><ArticleId IdType="pmc">PMC6930355</ArticleId><ArticleId IdType="pubmed">31495649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoja C, Wang JM, Bettoni S, Sironi M, Renzi D, Chiaffarino F, Abboud HE, Van Damme J, Mantovani A, Remuzzi G, et al. Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol. 1991;138:991&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886116</ArticleId><ArticleId IdType="pubmed">2012180</ArticleId></ArticleIdList></Reference><Reference><Citation>Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397&#x2013;411. doi: 10.1038/nri3452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3452</ArticleId><ArticleId IdType="pmc">PMC3807999</ArticleId><ArticleId IdType="pubmed">23702978</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu R, Guo C, Wang S, Huang Y, Jin O, Hu H, Chen J, Xu B, Zhou M, Zhao J, et al. Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol. 2017;69:1636&#x2013;1646. doi: 10.1002/art.40155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40155</ArticleId><ArticleId IdType="pmc">PMC5568813</ArticleId><ArticleId IdType="pubmed">28544564</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, Fu R, Zhou M, Wang S, Huang Y, Hu H, Zhao J, Gaskin F, Yang N, Fu SM. Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation. J Autoimmun. 2019;103:102286. doi: 10.1016/j.jaut.2019.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.05.014</ArticleId><ArticleId IdType="pmc">PMC6708470</ArticleId><ArticleId IdType="pubmed">31133359</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai M, Zhou T, Wang X, Shang M, Zhang Y, Luo M, Xu C, Yuan W. DC-SIGN expression on podocytes and its role in inflammatory immune response of lupus nephritis. Clin Exp Immunol. 2016;183:317&#x2013;325. doi: 10.1111/cei.12723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12723</ArticleId><ArticleId IdType="pmc">PMC4750597</ArticleId><ArticleId IdType="pubmed">26440060</ArticleId></ArticleIdList></Reference><Reference><Citation>Haymann JP, Levraud JP, Bouet S, Kappes V, Hag&#xe8;ge J, Nguyen G, Xu Y, Rondeau E, Sraer JD. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol. 2000;11:632&#x2013;639. doi: 10.1681/ASN.V114632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V114632</ArticleId><ArticleId IdType="pubmed">10752522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichinose K, Ushigusa T, Nishino A, Nakashima Y, Suzuki T, Horai Y, Koga T, Kawashiri SY, Iwamoto N, Tamai M, et al. Lupus Nephritis IgG induction of calcium/calmodulin-dependent protein kinase IV expression in podocytes and alteration of their function. Arthritis Rheumatol. 2016;68:944&#x2013;952. doi: 10.1002/art.39499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39499</ArticleId><ArticleId IdType="pmc">PMC6103450</ArticleId><ArticleId IdType="pubmed">26636664</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargava R, Lehoux S, Maeda K, Tsokos MG, Krishfield S, Ellezian L, Pollak M, Stillman IE, Cummings RD, Tsokos GC. Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis. JCI Insight. 2021;6:e147789. doi: 10.1172/jci.insight.147789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147789</ArticleId><ArticleId IdType="pmc">PMC8262331</ArticleId><ArticleId IdType="pubmed">33784256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruschi M, Moroni G, Sinico RA, Franceschini F, Fredi M, Vaglio A, Cavagna L, Petretto A, Pratesi F, Migliorini P, et al. Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): Prospective study. Rheumatology (Oxford) 2021;60:3388&#x2013;3397. doi: 10.1093/rheumatology/keaa793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa793</ArticleId><ArticleId IdType="pmc">PMC8516512</ArticleId><ArticleId IdType="pubmed">33351137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA. Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum. 2004;50:866&#x2013;870. doi: 10.1002/art.20103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20103</ArticleId><ArticleId IdType="pubmed">15022329</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaudineau Y, Deocharan B, Jousse S, Renaudineau E, Putterman C, Youinou P. Anti-alpha-actinin antibodies: A new marker of lupus nephritis. Autoimmun Rev. 2007;6:464&#x2013;468. doi: 10.1016/j.autrev.2007.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2007.02.001</ArticleId><ArticleId IdType="pubmed">17643934</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A, Lee K, D'Agati VD, Wei C, Fu J, Guan TJ, He JC, Schlondorff D, Agudo J. Bowman's capsule provides a protective niche for podocytes from cytotoxic CD8+ T cells. J Clin Invest. 2018;128:3413&#x2013;3424. doi: 10.1172/JCI97879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI97879</ArticleId><ArticleId IdType="pmc">PMC6063505</ArticleId><ArticleId IdType="pubmed">29985168</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113:1390&#x2013;1397. doi: 10.1172/JCI20402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI20402</ArticleId><ArticleId IdType="pmc">PMC406528</ArticleId><ArticleId IdType="pubmed">15146236</ArticleId></ArticleIdList></Reference><Reference><Citation>Greka A, Weins A, Mundel P. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2014;370:1263&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5176021</ArticleId><ArticleId IdType="pubmed">24670178</ArticleId></ArticleIdList></Reference><Reference><Citation>Khullar B, Balyan R, Oswal N, Jain N, Sharma A, Abdin MZ, Bagga A, Bhatnagar S, Wadhwa N, Natchu UCM, et al. Interaction of CD80 with Neph1: A potential mechanism of podocyte injury. Clin Exp Nephrol. 2018;22:508&#x2013;516. doi: 10.1007/s10157-017-1489-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-017-1489-3</ArticleId><ArticleId IdType="pubmed">29022109</ArticleId></ArticleIdList></Reference><Reference><Citation>Coers W, Brouwer E, Vos JT, Chand A, Huitema S, Heeringa P, Kallenberg CG, Weening JJ. Podocyte expression of MHC class I and II and intercellular adhesion molecule-1 (ICAM-1) in experimental pauci-immune crescentic glomerulonephritis. Clin Exp Immunol. 1994;98:279&#x2013;286. doi: 10.1111/j.1365-2249.1994.tb06138.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.1994.tb06138.x</ArticleId><ArticleId IdType="pmc">PMC1534396</ArticleId><ArticleId IdType="pubmed">7955534</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldwich A, Burkard M, Olke M, Daniel C, Amann K, Hugo C, Kurts C, Steinkasserer A, Gessner A. Podocytes are nonhematopoietic professional antigen-presenting cells. J Am Soc Nephrol. 2013;24:906&#x2013;916. doi: 10.1681/ASN.2012020133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2012020133</ArticleId><ArticleId IdType="pmc">PMC3665387</ArticleId><ArticleId IdType="pubmed">23539760</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Liu Y, He Y, Rong W, Zhang M, Li L, Liu Z, Zen K. Podocytes present antigen to activate specific T cell immune responses in inflammatory renal disease. J Pathol. 2020;252:165&#x2013;177. doi: 10.1002/path.5508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5508</ArticleId><ArticleId IdType="pubmed">32686090</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto A, Fujio K, Tsuno NH, Takahashi K, Yamamoto K. Kidney-infiltrating CD4+ T-cell clones promote nephritis in lupus-prone mice. Kidney Int. 2012;82:969&#x2013;979. doi: 10.1038/ki.2012.242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.242</ArticleId><ArticleId IdType="pubmed">22763816</ArticleId></ArticleIdList></Reference><Reference><Citation>May CJ, Welsh GI, Chesor M, Lait PJ, Schewitz-Bowers LP, Lee RWJ, Saleem MA. Human Th17 cells produce a soluble mediator that increases podocyte motility via signaling pathways that mimic PAR-1 activation. Am J Physiol Renal Physiol. 2019;317:F913&#x2013;F921. doi: 10.1152/ajprenal.00093.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00093.2019</ArticleId><ArticleId IdType="pmc">PMC6843047</ArticleId><ArticleId IdType="pubmed">31339775</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Yang X, Zhang X, An Z. Analysis of expression levels of IL-17 and IL-34 and influencing factors for prognosis in patients with lupus nephritis. Exp Ther Med. 2019;17:2279&#x2013;2283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6364195</ArticleId><ArticleId IdType="pubmed">30783486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Gao C, Cui S, Qin Y, Zhang C, Yi P, Di X, Liu S, Li T, Gao G, Zheng Z. Induction therapy downregulates the expression of Th17/Tfh cytokines in patients with active lupus nephritis. Am J Clin Exp Immunol. 2018;7:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6146154</ArticleId><ArticleId IdType="pubmed">30245920</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J, Li Y, Yang H, Zhang L, Yang B, Wang M, Li Q. Interleukin-17A participates in podocyte injury by inducing IL-1&#x3b2; secretion through ROS-NLRP3 inflammasome-caspase-1 pathway. Scand J Immunol. 2018;87:e12645. doi: 10.1111/sji.12645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12645</ArticleId><ArticleId IdType="pubmed">29446486</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan DH, Jia Y, Hassan OM, Xu LY, Wu XC. LPS-Treated podocytes polarize naive CD4(+) T Cells into Th17 and treg cells. Biomed Res Int. 2020;2020:8587923. doi: 10.1155/2020/8587923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8587923</ArticleId><ArticleId IdType="pmc">PMC7251438</ArticleId><ArticleId IdType="pubmed">32509873</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, Kaverina N, Utset TO, Meehan SM, Quigg RJ, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol. 2011;186:1849&#x2013;1860. doi: 10.4049/jimmunol.1001983.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001983</ArticleId><ArticleId IdType="pmc">PMC3124090</ArticleId><ArticleId IdType="pubmed">21187439</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21:605&#x2013;614. doi: 10.1038/s41590-020-0677-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0677-6</ArticleId><ArticleId IdType="pmc">PMC8135909</ArticleId><ArticleId IdType="pubmed">32367037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolovou K, Laskari K, Roumelioti M, Tektonidou MG, Panayiotidis P, Boletis JN, Marinaki S, Sfikakis PP. B-cell oligoclonal expansions in renal tissue of patients with immune-mediated glomerular disease. Clin Immunol. 2020;217:108488. doi: 10.1016/j.clim.2020.108488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108488</ArticleId><ArticleId IdType="pubmed">32479988</ArticleId></ArticleIdList></Reference><Reference><Citation>Senaldi G, Stolina M, Guo J, Faggioni R, McCabe S, Kaufman SA, Van G, Xu W, Fletcher FA, Boone T, et al. Regulatory effects of novel neurotrophin-1/b cell-stimulating factor-3 (cardiotrophin-like cytokine) on B cell function. J Immunol. 2002;168:5690&#x2013;5698. doi: 10.4049/jimmunol.168.11.5690.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.11.5690</ArticleId><ArticleId IdType="pubmed">12023368</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Ott KM, Yang J, Chen X, Wang H, Paragas N, Mori K, Li JY, Lu B, Costantini F, Schiffer M, et al. Novel regulators of kidney development from the tips of the ureteric bud. J Am Soc Nephrol. 2005;16:1993&#x2013;2002. doi: 10.1681/ASN.2004121127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2004121127</ArticleId><ArticleId IdType="pubmed">15917337</ArticleId></ArticleIdList></Reference><Reference><Citation>Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, McCarthy ET, Srivastava T, Domen J, Tormo A, Gauchat JF. Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family. J Immunol Res. 2015;2015:714964. doi: 10.1155/2015/714964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/714964</ArticleId><ArticleId IdType="pmc">PMC4471311</ArticleId><ArticleId IdType="pubmed">26146641</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos M, Poletti PT, Milhoransa P, Monticielo OA, Veronese FV. Unraveling the podocyte injury in lupus nephritis: Clinical and experimental approaches. Semin Arthritis Rheum. 2017;46:632&#x2013;641. doi: 10.1016/j.semarthrit.2016.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2016.10.005</ArticleId><ArticleId IdType="pubmed">27839739</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, Murphy ED, Roths JB, Dixon FJ. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med. 1978;148:1198&#x2013;1215. doi: 10.1084/jem.148.5.1198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.148.5.1198</ArticleId><ArticleId IdType="pmc">PMC2185049</ArticleId><ArticleId IdType="pubmed">309911</ArticleId></ArticleIdList></Reference><Reference><Citation>McGaha TL, Madaio MP. Lupus Nephritis: Animal modeling of a complex disease syndrome pathology. Drug Discov Today Dis Models. 2014;11:13&#x2013;18. doi: 10.1016/j.ddmod.2014.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ddmod.2014.08.002</ArticleId><ArticleId IdType="pmc">PMC4337231</ArticleId><ArticleId IdType="pubmed">25722732</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar RD, Castrezana-Lopez L, Allam R, Kulkarni OP, Segerer S, Radomska E, Meyer TN, Schwesinger CM, Akis N, Gr&#xf6;ne HJ, Anders HJ. Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. Immunology. 2009;128((1 Suppl)):e206&#x2013;e221. doi: 10.1111/j.1365-2567.2008.02948.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2008.02948.x</ArticleId><ArticleId IdType="pmc">PMC2753940</ArticleId><ArticleId IdType="pubmed">19175801</ArticleId></ArticleIdList></Reference><Reference><Citation>Maibaum MA, Haywood ME, Walport MJ, Morley BJ. Lupus susceptibility loci map within regions of BXSB derived from the SB/Le parental strain. Immunogenetics. 2000;51:370&#x2013;372. doi: 10.1007/s002510050632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002510050632</ArticleId><ArticleId IdType="pubmed">10803851</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312:1669&#x2013;1672. doi: 10.1126/science.1124978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1124978</ArticleId><ArticleId IdType="pubmed">16709748</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, Knagenhjelm J, Schwetje E, Chia YL, Tummala R, Lindholm C. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81:496&#x2013;506. doi: 10.1136/annrheumdis-2021-221478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId><ArticleId IdType="pmc">PMC8921596</ArticleId><ArticleId IdType="pubmed">35144924</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Houssiau FA. From sequential to combination and personalised therapy in lupus nephritis: Moving towards a paradigm shift? Ann Rheum Dis. 2022;81:15&#x2013;19. doi: 10.1136/annrheumdis-2021-221270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221270</ArticleId><ArticleId IdType="pubmed">34521616</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiger S, Ehreiser L, Anders J, Anders HJ. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. Front Immunol. 2022;13:999704. doi: 10.3389/fimmu.2022.999704.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.999704</ArticleId><ArticleId IdType="pmc">PMC9538665</ArticleId><ArticleId IdType="pubmed">36211360</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz GS, Nasr SH, Stokes MB, D'Agati VD. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5:607&#x2013;615. doi: 10.2215/CJN.07311009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.07311009</ArticleId><ArticleId IdType="pmc">PMC2849683</ArticleId><ArticleId IdType="pubmed">20203164</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao R, Liu Q, Zheng Z, Fan J, Peng W, Kong Q, He H, Yang S, Chen W, Tang X, Yu X. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS One. 2015;10:e132724. doi: 10.1371/journal.pone.0132724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0132724</ArticleId><ArticleId IdType="pmc">PMC4498640</ArticleId><ArticleId IdType="pubmed">26161538</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Fukusumi Y, Ivanov V, Zhang Y, Kawachi H. Tacrolimus ameliorates podocyte injury by restoring FK506 binding protein 12 (FKBP12) at actin cytoskeleton. FASEB J. 2021;35:e21983. doi: 10.1096/fj.202101052R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202101052R</ArticleId><ArticleId IdType="pubmed">34662453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Park Y, Jang SG, Hong SM, Song YS, Kim MJ, Baek S, Park SH, Kwok SK. Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus. Front Immunol. 2021;12:704526. doi: 10.3389/fimmu.2021.704526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.704526</ArticleId><ArticleId IdType="pmc">PMC8419414</ArticleId><ArticleId IdType="pubmed">34497607</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice WL, Van Hoek AN, P&#x103;unescu TG, Huynh C, Goetze B, Singh B, Scipioni L, Stern LA, Brown D. High resolution helium ion scanning microscopy of the rat kidney. PLoS One. 2013;8:e57051. doi: 10.1371/journal.pone.0057051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057051</ArticleId><ArticleId IdType="pmc">PMC3591388</ArticleId><ArticleId IdType="pubmed">23505418</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie JB, Helyer BJ. The immunology and pathology of NZB mice. Adv Immunol. 1968;9:215&#x2013;266. doi: 10.1016/S0065-2776(08)60444-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-2776(08)60444-7</ArticleId><ArticleId IdType="pubmed">4883742</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall AM, Ward FJ, Shen CR, Rowe C, Bowie L, Devine A, Urbaniak SJ, Elson CJ, Barker RN. Deletion of the dominant autoantigen in NZB mice with autoimmune hemolytic anemia: Effects on autoantibody and T-helper responses. Blood. 2007;110:4511&#x2013;4517. doi: 10.1182/blood-2007-06-094383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-06-094383</ArticleId><ArticleId IdType="pubmed">17785581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>